NCT-05914116

A Phase I/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti tumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors

It's a Phase I/2a study being conducted at multiple centers to investigate DB-1311, a new medicine. The study aims to assess its safety, how the body processes it, and its initial impact on advanced or metastatic solid tumors.

Phase I/2a study: A study that assesses the safety, effectiveness, and how well the treatment works

advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

metastatic: cancer that has spread from its original location or organ to other parts of the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05914116

Clinical Trial Site: Columbia

To see all available clinical trials click here.